Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies

Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors Funds will support advancement of lead programs through early clinical development, including Accent’s first-in-class DHX9 inhibitor and newly unveiled, potentially…